Supplemental Figure 1 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Year: 2023
Type: supplementary-materials
Abstract: Shown is the schema of study design and enrollment.(30) As noted, the cut-off for data analysis was May 15, 2015.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362404832